Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
38
ENTA Quote, Financials, Valuation and Earnings
Last price:
$14.09
Seasonality move
:
1.15%
Day range:
$13.93 - $14.46
52-week range:
$4.09 - $15.34
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
4.60x
P/B ratio:
6.28x
Volume:
246.1K
Avg. volume:
382.9K
1-year change:
65.18%
Market cap:
$406.7M
Revenue:
$65.3M
EPS (TTM):
-$3.84
Analysts' Opinion
-
Consensus RatingEnanta Pharmaceuticals, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 5 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $19.13, Enanta Pharmaceuticals, Inc. has an estimated upside of 35.74% from its current price of $14.09.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $11.00 representing 100% downside risk from its current price of $14.09.
Fair Value
-
According to the consensus of 6 analysts, Enanta Pharmaceuticals, Inc. has 35.74% upside to fair value with a price target of $19.13 per share.
ENTA vs. S&P 500
-
Over the past 5 trading days, Enanta Pharmaceuticals, Inc. has overperformed the S&P 500 by 0.96% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Enanta Pharmaceuticals, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Enanta Pharmaceuticals, Inc. has grown year-over-year revenues for 2 quarters straight. In the most recent quarter Enanta Pharmaceuticals, Inc. reported revenues of $15.1M.
Earnings Growth
-
Enanta Pharmaceuticals, Inc. has grown year-over-year earnings for 4 quarters straight. In the most recent quarter Enanta Pharmaceuticals, Inc. reported earnings per share of -$0.87.
Enterprise value:
418.9M
EV / Invested capital:
1.58x
Price / LTM sales:
4.60x
EV / EBIT:
--
EV / Revenue:
6.41x
PEG ratio (5yr expected):
-0.50x
EV / Free cash flow:
-13.02x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$60.7M
Return On Assets:
-24.72%
Net Income Margin (TTM):
-125.36%
Return On Equity:
-85.63%
Return On Invested Capital:
-26.42%
Operating Margin:
-121.56%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $79.2M | $67.6M | $65.3M | $14.6M | $15.1M | |
| Gross Profit | $76.8M | $65.3M | $60.7M | $14.1M | $13.8M | |
| Operating Income | -$137.2M | -$121.7M | -$85.3M | -$29.9M | -$18.4M | |
| EBITDA | -$134.8M | -$119.4M | -$80.8M | -$29.4M | -$17.1M | |
| Diluted EPS | -$6.37 | -$5.49 | -$3.84 | -$1.36 | -$0.87 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $319M | $311.7M | $422.8M | $299.9M | $204.3M | |
| Total Assets | $440.9M | $380.6M | $469.8M | $390.8M | $292.7M | |
| Current Liabilities | $36.2M | $29.8M | $62.8M | $57.5M | $48.6M | |
| Total Liabilities | $41.4M | $59.3M | $253.1M | $262M | $228M | |
| Total Equity | $399.4M | $321.3M | $216.7M | $128.8M | $64.7M | |
| Total Debt | $6.8M | $23.8M | $217.2M | $224.5M | $197.9M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$103.2M | -$78.8M | -$19.3M | -$10.4M | -$6.5M | |
| Cash From Investing | -$53.6M | $58.2M | $40.3M | $19.1M | $2.3M | |
| Cash From Financing | $198.1M | -$27.6M | -$26.6M | -$7.2M | -$8.3M | |
| Free Cash Flow | -$112.2M | -$96.7M | -$32.2M | -$19.4M | -$7.9M | |
ENTA
Sector
Market Cap
$406.7M
$28.4M
Price % of 52-Week High
91.85%
50.35%
Dividend Yield
0%
0%
Shareholder Yield
1.91%
-1.32%
1-Year Price Total Return
65.18%
-22.19%
Beta (5-Year)
0.965
0.521
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$13.98
200-day SMA
Buy
Level
$8.09
Bollinger Bands (100)
Buy
Level
7.59 - 11.95
Chaikin Money Flow
Buy
Level
18.5M
20-day SMA
Buy
Level
$12.75
Relative Strength Index (RSI14)
Buy
Level
69.84
ADX Line
Buy
Level
49.06
Williams %R
Sell
Level
-15.2482
50-day SMA
Buy
Level
$11.63
MACD (12, 26)
Buy
Level
0.86
25-day Aroon Oscillator
Buy
Level
68
On Balance Volume
Neutral
Level
12.9M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-1.3634)
Sell
CA Score
(Annual)
Level (-2.5122)
Buy
Beneish M-Score
(Annual)
Level (-3.4432)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (3.5146)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (6)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. The firm also conducts research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). The company was founded by Peter O. Kliem Martin Karplus, James Hogle, Gerard Wagner, Peter M. Howley, and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.
Stock Forecast FAQ
In the current month, ENTA has received 5 Buy ratings 1 Hold ratings, and 0 Sell ratings. The ENTA average analyst price target in the past 3 months is $19.13.
-
Where Will Enanta Pharmaceuticals, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Enanta Pharmaceuticals, Inc. share price will rise to $19.13 per share over the next 12 months.
-
What Do Analysts Say About Enanta Pharmaceuticals, Inc.?
Analysts are divided on their view about Enanta Pharmaceuticals, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Enanta Pharmaceuticals, Inc. is a Sell and believe this share price will drop from its current level to $11.00.
-
What Is Enanta Pharmaceuticals, Inc.'s Price Target?
The price target for Enanta Pharmaceuticals, Inc. over the next 1-year time period is forecast to be $19.13 according to 6 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is ENTA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Enanta Pharmaceuticals, Inc. is a Buy. 5 of 6 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ENTA?
You can purchase shares of Enanta Pharmaceuticals, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Enanta Pharmaceuticals, Inc. shares.
-
What Is The Enanta Pharmaceuticals, Inc. Share Price Today?
Enanta Pharmaceuticals, Inc. was last trading at $14.09 per share. This represents the most recent stock quote for Enanta Pharmaceuticals, Inc.. Yesterday, Enanta Pharmaceuticals, Inc. closed at $14.09 per share.
-
How To Buy Enanta Pharmaceuticals, Inc. Stock Online?
In order to purchase Enanta Pharmaceuticals, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get ENTA Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
ENTA
Sector
P/E ratio
--
23.66x
PEG ratio
-0.50x
-0.01x
P/B ratio
6.28x
1.84x
Price / LTM sales
4.60x
1.60x
Growth Metrics
ENTA
Sector
Revenue growth
3.55%
4.85%
Earnings growth
35.7%
11.15%
Revenue (5-year growth)
-11.81%
6.45%
Earnings forecast
-$1.01
-$0.20
Profitability
ENTA
Sector
Profitability FY 2025
$60.7M
$3.6M
Return on invested capital
-26.42%
-30.98%
Return on assets
-24.72%
-27.62%
Return on equity
-85.63%
-36.69%
Earnings Date
Last Earnings Date
Nov
17
Next Earnings Date
Feb
9
Estimated Next Earnings Date
Feb
16
Balance Sheet
ENTA
Sector
Total cash
$188.9M
$27.2M
Short term investments
$211M
$25.7M
Total assets
$292.7M
$79.9M
Long term debt
$197.9M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Buy
54
SMX alert for Dec 5
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 22.58% over the past day.
Buy
67
NUTX alert for Dec 5
Nutex Health, Inc. [NUTX] is up 18.9% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
